계명대학교 의학도서관 Repository

A randomized study of cisplatin and 5‑FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma

Metadata Downloads
Author(s)
Myeong Jun SongSi Hyun BaeHo Jong ChunJong Young ChoiSeung Kew YoonJun Young ParkKwang Hyub HanYoung Seok KimHyung Joon YimSoon Ho UmWoo Jin ChungJae Seok HwangSung‑Bum ChoJong Ryul Eun
Keimyung Author(s)
Chung, Woo JinHwang, Jae Seok
Department
Dept. of Internal Medicine (내과학)
Journal Title
Cancer Chemotherapy and Pharmacology
Issued Date
2015
Volume
75
Issue
4
Abstract
Purpose : This multicenter, randomized, open-labeled, clinical trial evaluated the efficacy and safety of cisplatin/5-fluorouracil (5-FU) hepatic arterial infusion chemotherapy (CF-HAIC) versus adriamycin adding to CF-HAIC (ACF-HAIC) in advanced HCC patients.
Methods : Fifty-six patients with advanced HCC were randomized to two treatment groups: (1) CF-HAIC group [n = 29, 5-FU, 500 mg/m2 on days 1–3, and cisplatin, 60 mg/m2 on day 2] and (2) ACF-HAIC group [n = 27, adriamycin, 50 mg/m2 on day 1, 5-FU, 500 mg/m2 on days 1–3, and cisplatin, 60 mg/m2 on day 2] every 4 weeks via an implantable port system. Primary efficacy endpoint was overall survival (OS). Treatment response and time to progression were secondary endpoints.
Results : Treatment response rates did not differ significantly between the two treatment groups. Time to progression (5.4 vs. 5.8 months, P = 0.863) and OS (11.1 vs. 8.8 months, P = 0.448) were not significantly different. When the factors affecting patient OS were analyzed, disease control rate [P < 0.001, HR 6.437 (95 % CI 2.580–16.064)] was independently associated with OS. Age (≥60 years) and serum AFP level (≥200 ng/dL) also were significant factors for OS [P = 0.007, HR 4.945 (95 % CI 1.543–15.850), P = 0.048, HR 2.677 (95 % CI 1.010–7.095), respectively]. Grade 4 treatment-related toxicity and mortality was not observed in both groups.
Conclusions : Although both HAIC regimens are safe and effective in patients with advanced HCC, HAIC adding adriamycin did not show delayed tumor progression and survival benefit compared to CF-HAIC in advanced HCC.
Keywords : Hepatocellular carcinoma – Hepatic arterial infusion chemotherapy – 5-Fluorouracil – Cisplatin
Keimyung Author(s)(Kor)
정우진
황재석
Publisher
School of Medicine
Citation
Myeong Jun Song et al. (2015). A randomized study of cisplatin and 5‑FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 75(4), 739–746. doi: 10.1007/s00280-015-2692-0
Type
Article
ISSN
0344-5704
Source
http://lps3.link.springer.com.proxy.dsmc.or.kr/article/10.1007%2Fs00280-015-2692-0
DOI
10.1007/s00280-015-2692-0
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/35291
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.